By Sanius Health
Artificial intelligence has become one of the defining technologies shaping modern drug discovery.
From identifying novel therapeutic targets to predicting protein structures and prioritising promising compounds, AI is enabling researchers to navigate scientific complexity with a speed and precision that would have been difficult to imagine even a decade ago.
These advances have rightly captured the attention of the pharmaceutical industry.
AI models are accelerating the earliest stages of research, helping scientists analyse vast quantities of biomedical literature, identify molecular relationships and generate hypotheses more efficiently than traditional approaches alone.
Organisations such as Isomorphic Labs, BenevolentAI and others are demonstrating how computational models can strengthen discovery pipelines and support the development of new medicines.
Yet as AI continues to mature, the conversation is beginning to shift. The question is no longer simply what artificial intelligence can do.
Increasingly, it is whether we are providing AI with the depth and quality of patient intelligence it needs to make meaningful scientific discoveries.
Every AI model ultimately learns from data. Its ability to identify patterns, generate hypotheses and support decision-making is fundamentally constrained by the information it receives.
While algorithms have advanced rapidly, the healthcare data underpinning them remains fragmented, episodic and, in many cases, incomplete.
As the industry looks towards the next generation of AI-enabled drug discovery, attention is turning from computational power alone to the richness of the evidence available to train it.
This distinction matters because discovering a promising molecule is only one part of the challenge.
Understanding how a disease develops, how patients experience it over time and why treatments succeed for some people but not others requires a different kind of intelligence altogether.
Artificial intelligence has already changed the way many organisations approach drug discovery.
Machine learning models can rapidly analyse genomic information, identify potential biological targets and predict how candidate compounds may interact with proteins. Protein structure prediction, once a major scientific bottleneck, has been dramatically accelerated through advances in AI.
Researchers are also using computational approaches to prioritise compounds, optimise molecular design and identify opportunities for drug repurposing, reducing both time and cost during the earliest stages of development.
These capabilities represent genuine progress. They enable researchers to investigate far more possibilities than traditional methods alone and focus valuable laboratory resources on the most promising candidates.
However, algorithms can only identify patterns that exist within the datasets available to them.
Many of today’s datasets remain heavily weighted towards controlled research environments. Clinical trials, while essential, are designed to answer specific scientific questions within carefully selected patient populations.
Routine clinical records often capture isolated moments of care rather than the continuous experience of living with a condition. Large volumes of valuable information about symptoms, treatment adherence, quality of life and disease progression frequently remain disconnected from the wider research ecosystem.
This is where the next evolution of drug discovery is beginning to emerge.
Increasingly, pharmaceutical research is becoming more patient-centred. Alongside understanding genes, proteins and molecular pathways, researchers are seeking to understand how diseases behave beyond the clinic.
Conditions evolve over months and years, not simply between scheduled appointments. Symptoms fluctuate, treatments change, adherence varies and patients experience diseases differently depending on their biology, behaviour and environment.
These factors are not peripheral to scientific discovery; they are becoming central to it.
A more complete understanding of the patient journey has the potential to influence biomarker identification, patient stratification, endpoint development and the design of future clinical studies.
It can reveal disease subtypes that may otherwise remain hidden, identify patients most likely to benefit from particular therapies and generate new hypotheses about disease progression that cannot easily be observed through traditional research methods alone.
Longitudinal patient intelligence is particularly valuable because it captures disease as a dynamic process rather than a series of isolated observations.
Instead of relying solely on snapshots collected during clinic visits, researchers can begin to observe patterns across months or even years.
They can examine symptom evolution, treatment switching, adherence, recovery trajectories and periods of stability or deterioration within the broader context of an individual’s everyday life.
For AI, this represents a significant shift. Rather than learning from static datasets alone, models can increasingly learn from continuous patient experiences.
The result is not simply more data, but more meaningful data: data that provides context, reveals relationships and reflects the complexity of real-world disease.
At the same time, digital health technologies are expanding what researchers can observe. Wearable devices now generate continuous measures relating to activity, sleep, heart rate, mobility and other physiological indicators.
As Sanius Health has seen across its work with patients and health systems, when combined with patient-reported outcomes, electronic health records and traditional clinical observations, these digital biomarkers provide an increasingly comprehensive picture of how health changes over time.
Importantly, they also help bridge the gap between clinical encounters.
Many meaningful changes occur long before a patient attends an outpatient appointment or reports worsening symptoms. Continuous monitoring offers researchers an opportunity to understand disease progression in far greater detail, potentially identifying early signals that would otherwise remain invisible.
This richer evidence base is creating new opportunities across pharmaceutical research.
Digital biomarkers may support the discovery of novel disease signatures, improve patient selection for clinical trials and contribute to more personalised approaches to treatment development.
They also strengthen our understanding of outcomes that matter most to patients, bringing lived experience closer to scientific decision-making.
Across the industry, organisations are therefore investing not only in AI capabilities but in connected patient intelligence. The greatest opportunity lies in integrating diverse sources of evidence into coherent longitudinal datasets that reflect how people actually experience disease.
Across Sanius Health’s ecosystem, the company sees this transition as one of the defining developments in modern healthcare research.
By bringing together longitudinal real-world evidence, patient-reported outcomes, wearable measures and digital biomarkers within large-scale patient ecosystems, it becomes possible to study disease in a far more connected way.
Rather than viewing clinical records, patient experience and physiological data as separate sources of information, they become complementary parts of the same scientific picture.
This integrated approach provides researchers with greater context.
It allows AI models to learn not only from molecular data but from the lived experience of patients over time, supporting the generation of more informed hypotheses and contributing to a deeper understanding of disease behaviour across diverse populations.
Artificial intelligence will undoubtedly continue to shape the future of drug discovery. Computational models will become more sophisticated, analytical techniques will continue to evolve and our ability to explore biological complexity will only increase.
However, the future of pharmaceutical innovation will depend on more than increasingly powerful algorithms. It will depend on the quality, continuity and connectedness of the patient intelligence that informs them.
The next generation of medicines will emerge not simply from teaching AI to think faster, but from enabling it to learn more deeply from the realities of human health.
As healthcare becomes increasingly connected, the greatest advances in drug discovery will come from combining computational innovation with longitudinal patient intelligence; providing researchers with a richer understanding of disease and, ultimately, a stronger foundation on which to develop the medicines of tomorrow.
To learn more about the work Sanius Health is doing to support drug discovery, get in touch with the team at: [email protected]
